Agreements reached under this partnership
Joint research agreement- 1
The companies will work to develop compounds expected to exhibit new properties by creating conjugates of drugs being researched and developed by SK Plasma and RIBOMIC's aptamer.
- 2
The companies will advance research in this field by leveraging their respective research and development expertise.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on the earnings forecast for the fiscal year ending March 2027 is expected to be reflected in the earnings forecast for the fiscal year ending March 2027, which is scheduled to be announced in due course.
| Item | Details |
|---|---|
| Name of alliance partner | SK Plasma Co., Ltd. |
| Alliance partner's business activities | Research and development, manufacture, and sale of plasma-derived products and other products |
| Alliance partner's location | Republic of Korea, 310, Pangyo-ro, Bundang |
| Alliance partner's capital | KRW 9,876,683,500（as of the end of FY2025） |
| Type of alliance | Joint research agreement |
| Details of the alliance | The companies will work to develop compounds expected to exhibit new properties by creating conjugates of drugs being researched and developed by SK Plasma and RIBOMIC's aptamer., The companies will advance research in this field by leveraging their respective research and development expertise. |
| Date of board resolution | 16 April 2026 |
| Impact on Business Performance | The impact of this matter on the earnings forecast for the fiscal year ending March 2027 is expected to be reflected in the earnings forecast for the fiscal year ending March 2027, which is scheduled to be announced in due course. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The companies will work to develop compounds expected to exhibit new properties by combining SK Plasma's drug with RIBOMIC's aptamer, and will advance the research by leveraging both companies' research and development expertise.